# Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms

> **NCT03005119** · PHASE2 · UNKNOWN · sponsor: **PhytoTech Therapeutics, Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** PTL201
- **DRUG:** Placebo Oral Capsule

## Key facts

- **NCT ID:** NCT03005119
- **Lead sponsor:** PhytoTech Therapeutics, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2017-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03005119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03005119, "Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03005119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*